News | May 28, 2021
Bharat Biotech signs MoU with GCVC for COVID Vaccine
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
The facility is expected to be completed in 2024
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
